Gallant is an animal health biotechnology company based in San Diego developing off-the-shelf stem cell therapies for dogs and cats. Its lead product targets refractory Feline Chronic Gingivostomatitis (FCGS) and is on track for FDA conditional approval in early 2026, which could become the first FDA-labeled allogeneic stem cell therapy in veterinary medicine. Gallant's proprietary platform harnesses uterine-derived mesenchymal stem cells and the company is advancing a pipeline that includes therapies for canine and feline osteoarthritis, canine atopic dermatitis, and feline chronic kidney disease. The company positions its therapies as ready-to-use, science-backed products developed under FDA oversight to address disease root causes rather than only managing symptoms. With the recently closed $18 million Series B, Gallant plans to accelerate initial commercial rollout of its FCGS therapy while continuing development across its pipeline. Leadership emphasizes development, manufacturing, and commercialization expertise with the stated mission of making regenerative medicine accessible to pets in need. Gallant offers stem-cell collection and lifetime banking services for pets, collecting tissue during routine spay/neuter procedures and harvesting younger stem cells for future treatments. The company charges $395 to collect and $595 for lifetime storage (or $95/year), with treatments priced at $300; it is waiving the initial collection fee for its launch. Gallant says veterinarians from its acquired business have already treated hundreds of cats and dogs with banked stem cells for conditions including osteoarthritis, atopic dermatitis, torn ligaments and chronic dry eye, and that those treatments have shown efficacy in early clinical trials. The business acquired the veterinary division of Cook-Regentec, including IP, existing stem cell banking operations and a pipeline of cell therapy products derived from reproductive tissue. Gallant's mission is to expand access to regenerative medicine for dogs nationwide, leveraging the high volume of routine spay/neuter procedures as a collection channel.

Total raised

$44M

Funding rounds

3

Latest round

Series B

Latest activity

Jun 2025